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The role of the gut microbiome in human health and disease with a particular emphasis on therapeutic use of
probiotics under specific medical conditions was mainly highlighted in 1st Annual conference of Probiotic
Association of India (PAi) and International Symposium on “Probiotics for Human Health - New Innovations and
Emerging Trends” held on 27th-28th August, 2012 at New Delhi, India. There is increasing recognition of the fact
that dysbiosis or alteration of this gut microbiome may be implicated in gastro-intestinal disorders including
diarrheal diseases, ulcerative colitis, inflammatory bowel diseases, life style diseases viz. Diabetes Mellitus-2 and
obesity etc. This report summarizes the proceedings of the conference and the symposium comprehensively.
Although, research on probiotics has been continuing for the past few decades, the subject has been currently the
major focus of attention across the world due to recent advances and new developments in genomics,
transcriptomics, proteomics, metabolomics and emergence of new generation of high through put sequencing
technologies that have immensely helped in understanding the probiotic functionality and mode of action from
nutritional and health perspectives. There is now sufficient evidence backed up with good quality scientific clinical
data to suggest that probiotic interventions could indeed be effective in various types of diarrheal diseases, other
chronic gastrointestinal inflammatory disorders like pouchitis, necrotizing entero-colitis, allergic responses and
lactose intolerance etc. This report makes a modest attempt to give all the stake holders involved in development
of probiotic based functional/health foods an overview of the current status of probiotics research at the Global
and National level. The most crucial issues that emerged from the lead talks delivered by the eminent speakers
from India and abroad were the major focus of discussions in different plenary and technical sessions. By discussing
some of these issues from scientific perspectives, the conference could achieve its prime objective of disseminating
the current knowledge on the prospects of probiotics as potential biotherapeutics in the management of human
health and diseases.
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Probiotics constitute the new buzz word in human diet-
ary portfolio and are currently the major focus of atten-
tion across the world including India and other
developing counties due to their enormous health poten-
tials. Our understanding of the functionality of human
gut microbiota and increasing use of probiotic organisms
specifically lactobacilli and bifidobacteria as functional
microbial dietary ingredients for promoting human
health have made considerable impact on the consu-
mers. As s result of recent advancements in the science* Correspondence: vkbatish@gmail.com
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reproduction in any medium, provided the orof probiotics in terms of efficacy, mode of action,
probiotic- gut microbiota-host interactions at molecular
level with the help of high through put sequencing tech-
niques and nutrigenomics, the application of probiotics
offers an innovative approach for development of novel
probiotic formulations under the category of functional
foods for the management of specific diseases particu-
larly chronic inflammatory gastrointestinal disorders and
other medical conditions. However, specific health
claims associated with probiotics/ probiotic food formu-
lations and their safety through scientific evidence based
clinical studies in the target human population remain a
real challenge to establish the credibility of their health
promoting functions. Nonetheless, this limitation doesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mote human health and confer protection against dis-
eases besides introducing lot of value to the foods from
nutritional perspectives. In view of the significant im-
pact, these invaluable food-grade microbial-ingredients
are likely to make on nutritional well being and public
health, it was considered highly appropriate to do some
brain storming on the most critical emerging issues.
Some of the pertinent issues related to probiotic func-
tionality which need immediate attention for in depth
discussions at an open platform include efficacy and
safety of probiotics, establishing their health claims
against specific diseases in the target subjects both
in vitro and in vivo models, their mode of action and
validation in well designed clinical studies, probiotic
product development, effective dosage, stability and sur-
vival of probiotics during processing and storage and
regulatory issues etc. Addressing these issues holistically
through mutual discussions with all the concerned stake
holders could pave way in developing a road map for fu-
ture endeavors on these lines in the effective usage of
probiotics for the welfare of the society in the country.
Realizing the enormous prospects and significance of
probiotics in human health in the backdrop of the afore-
said issues from global perspective and the tremendous
feedback received from the industry, the concept of Pro-
biotic Association of India (PAi) was mooted and subse-
quently the same was got registered as a society with
effect from Dec. 8, 2010. Backed up with more than 200
registered members represented by faculty and students
from academic organizations and industry as corporate
members, PAi initiated the process of organizing its first
annual conference from a broader perspective to give a
global touch to this scientific event by clubbing it with
an International symposium with the theme title
“Probiotics for Human Health- New Innovations and
Emerging Trends”. Accordingly, the 1st Annual Confer-
ence of PAi and International Symposium on “Probiotics
for Human Health- New Innovations and Emerging
Trends” was organized on 27th-28th August, 2012 at
India Habitat Centre, Lodi Road, New Delhi. The con-
ference was attended by about 200 participants from
different parts of India and abroad. The eminent
speakers invited for delivering their lead papers in
their respective areas of interest in probiotic research
in different plenary and scientific sessions of the con-
ference included seven from abroad representing Fin-
land, Spain, Ireland, UK/Scotland, Australia, Denmark
and Hong Kong and nine from India. Three of the
overseas speakers in the conference were nominated
by International Scientific Association of Probiotics
and Prebiotics (ISAPP). The proceedings of the two
day conference as per the program schedule are sum-
marized below.Session on oral presentations by young researchers
The conference began with a session on oral presenta-
tions by young researchers to present and exchange new
data and cutting edge ideas in the field of probiotics. A
total of six young researchers presented their recent
work on probiotics in their respective areas of research
and their performance was monitored by an expert panel
of three judges comprising of Dr. C.S. Yajnik, Director,
Diabetes Unit King Edward Memorial Hospital, Pune,
India; Dr. Karen Scott, Rowett Institute of Nutrition and
Health, Scotland, UK and Dr. Nagendra Shah, Professor
of Food Science, University of Hong Kong, Hong Kong.
Ms Suja Senan from GAU, Anand, Gujarat, the first
speaker in the session presented her work on the
annotation of complete whole genome sequence of
Lactobacillus helveticus MTCC 5463 [1], the indigenous
probiotic strain (claimed to exhibit significant antimicro-
bial activity, lowering of cholesterol in humans along
with expressing positive immuno-modulating effects)
from safety perspective. She particularly targeted anti-
biotic resistance, production of harmful metabolites, po-
tential virulence factors, biogenic amines, D-lactic acid,
azoreductase and nitroreductase as the potential car-
cinogenic biomarkers at the gene sequence level to dwell
on their role in the safety of the aforesaid strain. Based
on the complete whole genome sequence analysis, she
concluded that a detailed bio-informatic analysis related
to biosafety of probiotic strain MTCC 5463 could pro-
vide very useful information on its genomic stability,
antibiotic resistance, virulence and production of
harmful metabololites. While addressing the concerns
raised over the possibility of antibiotic resistance transfer
to the gut microbiota, the absence of mobile genetic
elements and chromosomally-encoded antibiotic resist-
ance mechanisms in this indigenous probiotic strain,
Ms Suja stated that in-silico analysis of the whole gen-
ome sequence could satisfy the queries with regard to its
overall safety.
Ms Ruchi Vaidya from M. S. University of Baroda,
Vadodara, Gujarat made a presentation of her recent
work on the outcome of a cross sectional study designed
to determine the associations of gut microbiota on glu-
cose and lipid response in Type 2 diabetic patients.
While sharing the data on the key findings of this study,
she revealed that almost 77% of the subjects had poor
control of diabetes as could be reflected from high
values of HbA1c FBS and PP2BS concentrations in the
blood. The mean cholesterol and triglyceride levels of
the subjects were also on the higher side. Almost 62%
of the subjects had considerably high LDL and 61%
had poor HDL levels. While commenting upon the
changes in the gut microflora in the subjects of the
study, she further stated that there was heavy co-
lonization of Lactic acid bacteria and Bifidobacteria
Grover et al. Gut Pathogens 2012, 4:15 Page 3 of 14
http://www.gutpathogens.com/content/4/1/15that showed a significant negative association with
HbA1c, TG, VLDL and TC/HDL ratio (p<0.05) along
with BMI. Fat intake of the subjects also showed a
strong negative association with fecal LAB and bifido-
bacterial counts and a positive association with enteric
pathogens where as fibre intake and intake of probiotics
and prebiotic rich foods showed a vice versa asso-
ciations with the fecal microbial counts. Lactic acid
bacteria and bifidobacteria were significantly low in
subjects with presence of 3 or more diabetic compli-
cations where as enteric pathogen counts were higher.
She concluded that the type of microbiota established
in the gut plays a significant role in arresting the compli-
cations of Type 2 DM.
Dr Raj Kumar Duary from Tezpur University, Napaam,
Assam spoke about his work on the functional efficacy of
two indigenous probiotic Lactobacillus plantarum strains
with regard to their acid and bile tolerance, hydrophobi-
city, adherence property, role of surface layer proteins
in colonization, mucosal barrier function, anti-inflam-
matory and immuno-modulatory effects on HT-29 cells.
He briefed the audience that after mass screening
of indigenous putative probiotic lactobacilli based on
their hydrophobicity and cell adhesion property on
HT-29 and Caco-2 cell lines, Lp9 and Lp91 were short-
listed for quantification of relative expression of the
genes involved in acid and bile tolerance along with
colonization potentials under in vitro conditions simu-
lating gut environment as well as their immuno-
modulatory functions in HT-29 cells by RT-qPCR [2].
Lp91 exhibited relatively higher acid tolerance by up-
regulating the relative expression ‘atpD’ gene at pH 2.5
after 90 min [3]. Expression of ‘bsh’ gene was also up-
regulated maximally in both the selected strains under
2% bile concentration with maximum attained with
Lp91 [4]. In the context of surface proteins, ‘mub’ gene
was maximally expressed in Lp9. Almost, the same
trend was recorded in the expression of ‘mapA’ in Lp9.
‘EF-Tu’ gene, on the other hand, was expressed highest
in Lp91. However, there were inter strain variations in
respect of the expression of all the three surface pro-
teins. Both the probiotic strains demonstrated strong
immuno-modulatory and anti-inflammatory properties
by up regulating MUC2, anti-inflammatory cytokines
and other signaling molecules [5]. Lp91 was rated as the
most effective by significantly up regulating IL-10 and
IFN-α expression in HT-29 cells under pre-culturing
conditions. He finally concluded that Lp91 and Lp9
were the most promising indigenous probiotic strains
and have the prospects to be explored as potential
biotherapeutics against inflammatory disorders.
Mr. Umesh Kumar from NDRI, Karnal was the next
young researcher who presented his work on the anti-
allergic effect of dahi made with Lactobacillusacidophilus and Bifidobacterium bifidum in mice. While
presenting his data, he informed that feeding of pro-
biotic dahi significantly suppressed (p<0.001) the eleva-
tion of whey proteins-specific IgE and IgG response in
the serum of WP-sensitized mice. In addition, sIgA
levels were significantly (p<0.001) increased in intestinal
fluid collected from mice fed with La-Dahi or LaBb-
Dahi. Production of Th-1 cell-specific cytokines i.e.
interferon-γ (IFN-γ), interleukin-12 (IL-12) and IL-10
increased; while Th2-specific cytokines (IL-4) decreased
in the supernatant of 48 hr cultured splenocytes col-
lected from mice fed with probiotic dahi compared to
the other groups. Moreover, the splenic mRNA levels of
IFN-γ, interleukin-10 were significantly increased with
concomitant decrease in the expression of IL-4 in La-
Dahi or LaBb-Dahi groups, as compared to control
groups. From the outcome of this study, he concluded
that probiotic dahi suppressed WP-induced allergic con-
sequences characterized by decreasing levels of IgE, IgG
in serum and increasing intestinal sIgA levels. Cytokines
profile also indicated the shift from skewed Th2-
pathway to cytotoxic Th1-pathway for attaining balance.
Mr. Himanshu Kumar from NCCS, Pune in his pres-
entation focused on exploring the microbial diversity of
Kutajarista, an Indian Ayurvedic preparation in quest for
finding novel probiotic strains. He demonstrated that
microbial diversity in Kutajarista increased after 8th day
of fermentation but gradually decreased with only 3 op-
erational taxonomic units (OTU’s) recovered at the sat-
uration of fermentation. Amongst the microbial types,
Lactobacillus spp. was found at initial time point of fer-
mentation. When assessed for probiotic attributes,
Lactobacillus plantarum isolated from Kutajarista was
highly resistant to acidic pH 2, 0.3% bile concentration
and simulated gastric juice [6]. L. plantarum also
adhered HT-29 cells and colonized mouse gut as
revealed by FACS and confocal analysis. He further sta-
ted that the maximum colonization of the probiotic
Lactobacillus plantarum occurred at colonic part of the
intestine. The antibacterial activity of L. plantarum
against enteric pathogens was also demonstrated along
with amelioration of cytotoxicity caused by Aeromonas
veronii in Vero cell line. Besides this, disruption of tight
junction proteins in MDCK cell line induced with the
same pathogen was prevented by L. plantarum.
Immuno-modulatory and anti-inflammatory roles of L.
plantarum were also demonstrated in mouse macro-
phage RAW cells activated by A. veronii. Lactobacillus
plantarum strain from Kutajarista was stable for 14 days
in comparison to 8 days with commercial GG strain.
Furthermore, the viability of Lactobacilli in Kutajarista
was found to be enhanced further when co-cultured
with Saccharomyces cerevisiae isolated from the same
product suggesting specific interaction between these
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matrix. This study highlights the potential use of alterna-
tive sources like ayurvedic preparations for isolation of
indigenous probiotic microbes. Kutajarista has unique
therapeutic properties for gastrointestinal disorders and
therefore, it could be an excellent vehicle for incorpor-
ation of these strains.
Mr. Satvinder Singh from NDRI, Karnal was the last
speaker in the session to present his findings on the
anti-diabetic potential of two Lactobacillus rhamnosus
strains against type 2 diabetes in a rat model. Diabetes
was induced in rats fed with high fat diet followed by
streptozotocin and divided into three groups viz. two
probiotics and one control. He presented the data on
the antioxidative effects of the two strains in terms of
total anti-oxidative property (TBARS) and activities of
anti-oxidative enzymes viz., catalase, superoxide dismu-
tase (SOD) and glutathione peroxidase (GPx) in liver
and erythrocytes. Besides this, expression of proglucagon
and prohormone convertase1 (PC1) genes in cecum, and
TNF-α, IL-6 and adiponectin in epididymal fat were also
investigated by real-time PCR. Amongst the two experi-
mental groups based on two distinct Lactobacillus
rhamnosus strains, HFD+17 group had improved oral
glucose tolerance test, lower FBG, GHb, free fatty acids,
triglycerides, total cholesterol, LDL-cholesterol and
atherogenic index, and higher plasma insulin and HDL-
cholesterol after 3 and 6 weeks of feeding. Even though
the total number of bacteria was same in the two experi-
mental groups, HFD+17 had more bifidobacteria and
lactobacilli in comparison to HFD+LGG. Relative propi-
onate proportions (%) were significantly lower in case of
HFD+17 than HFD+SM and HFD+LGG groups. HFD+17
group had significantly lower TBARS and increased activity
of catalase, SOD and GPx in liver and erythrocytes.
Similarly, HFD+17 group showed increased expression of
proglucagon and PC1 and decreased expression of TNF-α
and IL-6 genes. It can be concluded from the study that L.
rhamnosus NCDC 17 does have anti-diabetic effect through
enhancing the beneficial bacteria, activities of anti-oxidative
enzymes and expression of incretin hormone, and lowered
propionate, TBARS and expression of inflammatory mar-
kers in diabetic rats.
Inaugural session
The conference inaugural session began with the
welcome address given by Dr. A. K. Srivastava Director,
National Dairy Research. Institute, Karnal and President,
Probiotic Association of India. Dr. Srivastava welcomed
the delegates and apprised them with the theme of the
International symposium on probiotics. He presented a
comprehensive overview of the conference scientific
programme with major focus on multi-dimensional role
of probiotics in human health and well being. Dr.Srivastava comprehended that probiotics as functional
foods, dietary supplements and bio-therapeutics are be-
coming increasingly popular amongst the health con-
scious consumers, health care professionals besides the
research scientists across the world as the scientific evi-
dence continues to accumulate on their enormous
health potentials along with their possible mode of ac-
tion. The continuing emergence of clinical evidence for
benefits to consumers and the subsequent marketing
power of these microbial ingredients have now seen pro-
biotics becoming the fastest growing category of func-
tional and health foods. By virtue of expressing a wide
spectrum of novel physiological functions beneficial to
human health, probiotics are currently being recognized
as the grey area of intensive investigations at the global
level to derive their beneficial health effects maximally
for the welfare of society from nutritional and health
perspectives. However, he cautioned that before seeking
any specific health claim for any medical condition
attributed to a particular probiotic strain or the food for-
mulation developed with the same, it must be validated
through well designed double blind placebo controlled
clinical studies at least at two differently located centers.
The conference was formally inaugurated by Mr. T.
Chandramouli, Chairperson, FSSAI, who in his inaugural
address highlighted the initiatives being taken at FSSAI
for regulating the quality, efficacy and safety of pro-
cessed foods including the value added functional foods
particularly dairy based enriched with probiotics to con-
fer their beneficial effects on human health and well
being. He called upon the delegates and the probiotic
fraternity in the country to deliberate at length on the
key issues and challenges before the probiotic industry
and suggest possible solutions to address these problems
for judicious and effective usage of probiotics in the
country for the benefit of the consumers and the society
through their innovative R&D initiatives. He also sought
the help of distinguished scientists having adequate
expertise in probiotic research to advise the food au-
thority how to sustain the quality, efficacy and safety of
probiotic formulations in food format and as supple-
ments in the Indian market in the backdrop of many
spurious probiotic products with false claims entering
the Indian market. Dr. Seppo Salminen from Finland
also spoke on the immense value of probiotics for
health applications. Dr. G. P. Talwar also shared his
views on the prospects of exploring probiotic therapy in
vaginal health to further extend the scope of probiotic
applications. In the end, Dr. V. K. Batish, Secretary, PAi
and the Organizing Secretary of the conference pro-
posed a vote of thanks to all the delegates and expressed
his deep sense of gratitude to the invited speakers for
agreeing to present their key-note addresses and lead
papers in the conference.
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documented health benefits
Probiotics have a long global history of traditional use
[7]. The tradition of using probiotic microorganisms for
health benefits is now backed by strong scientific evi-
dence with promising strains of probiotics in the preven-
tion and treatment of diseases [8]. Although promising,
many probiotics are hindered by inherent physiological
and technological weaknesses. Thus, new scientific inno-
vations with meta-biotechnlogy and patho- biotechnol-
ogy approaches in the screening and designing of
probiotics for particular health benefits may provide
strong scientific support for future probiotic research. To
deliberate on this particular topic, Dr. Seppo Salminen,
Professor and Director, Functional Foods Forum, University
of Turku, Finland was invited to deliver the key note ad-
dress covering the entire journey of probiotics starting from
basic probiotic concept, definition, brief history of probio-
tics, their origin, foods as a carrier of probiotics, their safety
and efficacy along with regulatory issues and future per-
spectives. The main focus of his address was on proving
specific health claims associated with probiotics through
well designed scientifically driven evidence based clinical
studies to enhance their credibility in terms of their claimed
functional efficacy. He highlighted the importance of
microbiota acquisition from mothers prior to or during
delivery that provide first stimuli for the maturation of the
intestinal immune system and development [9] and
conveyed that establishment of microbiome contributes to
the maintenance of intestinal homeostasis and mucosal
barrier function and any aberrations in that may lead to
non-optimal microbiota and predispose them to subse-
quent diseases. Elaborating his statement, Dr. Salminen
stated that early establishment of a healthy gut microbiota
hallmarked by that of a healthy breastfed infant, provides
the key to long-term well- being. Furthermore, breastfed
infants have less allergies, diarrhea, respiratory and gastro-
intestinal infections due to the characteristics composition
and properties of breast milk including presence of high
levels of bifidobacteria and lactic acid bacteria [10]. The
predominance of bifidobacteria has an important impact
on later health and promotion of such microbiota has been
taken as a target for nutritional intervention in infants. He
also cautioned that although the probiotic science has
developed rapidly and the technological and health proper-
ties of many probiotics are well defined yet, there is a need
to evaluate the impact of manufacturing and food matrices
on stability of probiotic properties and quality. Speaking
about the limitations of the existing probiotic strains avail-
able in the market, Dr. Salminen opined that new probio-
tics are still required for enhancing the resilience of healthy
microbiota and also emphasized that the quest for novel
strains should continue to address other targets such as
allergy prevention, alleviation of obesity development,dental caries risk reduction, irritable bowel syndrome
symptom relief, reduction in the risk of respiratory tract
infections and prevention of necrotizing enterocolitis etc.
These initiatives also require new human intervention
studies for establishing health claims for probiotics and
advocating their use as nutritional adjuncts to other
therapies [11].
Gut microbiota in human health and disease
Trillions of microbes inhabit the human intestine,
forming a complex ecological community that influences
normal physiology and susceptibility to disease through
complex host microbial interactions [12]. The distortion
in the gut microbial composition may lead to chronic
diseases such as autoimmune diseases, colon cancers,
gastric ulcers and life style diseases like obesity, type 2
diabetes and cardiovascular disease [13]. To ponder
upon this crucial issue, Dr. F. Guarner, Consultant of
Gastroenterology, Digestive System Research Unit,
University Hospital Vall d’ Hebron, Barcelona, Spin,
while delivering his key note presentation spoke on
“Gut Microbiota and Digestive Health”. Deliberating the
importance of probiotics in human health, he discussed
the metabolic, defensive and trophic functions of gut
microbiota to host health. He emphasized that it is the
host that provides habitat and nutrition to microbial
communities: in fact, we feed gut microbiota. Microbial
symbionts have been evolutionary adapted to provide
the required organic compounds (essential amino acids,
vitamins) and the ability to obtain energy from different
sources. Further highlighting the importance of com-
mensal gut microbiota in human health and its impact
on shaping the immune defense mechanisms in the host,
Dr. Guarner threw some light on how gut microbes play
an essential role in the development of a healthy
immune system as could be evidenced from studies in
the germ-free animals. Reiterating his view point on this
issue based on the findings of some recent studies, he
enlightened the audience that some gut commensals
play a major role in the induction of regulatory T cells in
the gut lymphoid follicles [14]. The outcome of these
studies clearly suggests that control pathways mediated
by regulatory T cells are essential homeostatic mechan-
ism by which the host can tolerate the massive burden
of innocuous antigens within the gut or on the body sur-
faces without resulting in inflammation [15]. Continuing
further, Dr. Guarner contended that besides several
other factors, foods and dietary fibers have a significant
impact on the gut microbial ecosystem in terms of both
composition and functions and stated that several facts
support this notion. Non-digestible carbohydrates and
proteins present in foods and fibers are the two main
fermentative substrates in the colon. The amount of
ingested dietary fiber is a principal factor determining
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term dietary pattern influence microbial composition
and enterotypes [16]. Finally, he concluded that both
probiotics and prebiotics have been explored thoroughly
to improve metabolic activity, composition and symbiotic
relationships of the gut microbes with the host [17].
Probiotics as future biotherapeutics to contain diabetes
Dr. M. Balasubramanyam, Assistant Director & Senior
Scientist from Madras Diabetes Research Foundation,
Chennai delivered his talk on exploring the prospects of
novel dietary based strategies including probiotic and
prebiotic interventions in the management of Type 2
diabetes by modulating gut hormones. Elaborating on
this aspect, he conveyed that with the discovery of gut
hormones (the so called incretins viz. GLP-1 and GIP)
and their implications in glucose homeostasis, the
‘gut connection’ to type-2 diabetes has now been estab-
lished beyond peripheral insulin resistance and beta cell
failure. In order to substantiate the validity of this
hypothesis, he came across with some observations that
microbial populations in the gut are different in obese
and lean subjects and similarly in diabetic from non-
diabetics suggesting that obesity/diabetes may have a
different microbial component [18]. Considering the link
between alterations in intestinal microbiota and
metabolic diseases, Dr. Balasubramanyam claimed that
probiotic interventions could serve as potential modula-
tors of gut-flora that change the gut composition in a
beneficial manner and exert various health beneficial
effects on the host. He further pointed out that certain
strains of Lactobacillus spp. reported to decrease body
fat percentage in healthy volunteers exerted a beneficial
effect on the onset of diet-induced obesity by reducing
the cell size of white adipose tissues. Realizing the
immense potential and scope of using the novel dietary
based strategies to effectively control type-2 diabetes, he
called upon the researchers that in order to safely and
effectively change human gut microflora, the future
research endeavors need to be focused to highlight the
complex hormonal, immune-modulatory and metabolic
mechanisms underlying microbioata-host interactions in
different tissues. Furthermore, he stressed that the
candidate treatments should be evaluated in well-
designed trials with patient-oriented end-points.
In the next presentation, Dr. Anura Kurpad, Professor
of Physiology and Nutrition at St. John’s Medical
College, Bangalore spoke on the role of gut microflora in
meeting the body’s daily requirements of indispensable
amino acid (IAA) as per the new WHO/FAO recom-
mendations (2007) which are three fold higher than the
previous recommendations. Therefore, the intake of
limiting amino acids such as lysine in undernourished
populations is likely to be marginally deficient since,these populations also eat a high amount of starch in
their predominantly cereal based diets and some starch
escapes digestion and absorption in the small intestine
and is available for microbial fermentation in the lower
reaches of the small intestine and colon for contributing
towards the intake of IAAs in the body. Elaborating fur-
ther on this important subject, Dr. Kurpad enlightened
the gathering that the source of nitrogen used for micro-
bial synthesis of IAA could come from urea salvage, or
from ingested dietary protein, or endogenous protein
secretions. The relationship between requirement and
supply of N, and microbial IAA contribution is highly
complex, given that urea salvage could be the key to
nutritionally significant microbial IAA contribution. He
further stated that when N intake is low, the recycling of
urea would be of most positive benefit to the body in
terms of IAA homeostasis. He further pointed out that
although the potential to modulate IAA contribution
through the provision of microbial substrate remains un-
known, it does have important biological consequences.
It might partly explain how undernourished populations
living on cereal based low quality protein intakes, evolve
alternative mechanisms to meet IAA demands and
hence adapt and survive.
Dr. Sharmila Mande, Principal Scientist and Head,
TCS Innovation Labs, Tata Consultancy Service Ltd.,
Pune while presenting the global scenario of malnutrition
in her talk highlighted the importance of metagenomics for
understanding the role of gut microflora in malnourish-
ment. She further elaborated that by facilitating a direct
investigation of the gut microflora, the metagenomics
approach aids researchers to obtain a comprehensive
understanding of how the variation of the gut microbiome
affects human health. She discussed a metagenomic
approach for analyzing the difference between gut micro-
bial communities obtained from a malnourished and an
apparently healthy child [19]. The analysis of this study
showed that malnourished child gut was deficient in several
groups like Lactobacillus and Bifidobacteria but harboured
an abundance of enteric pathogens. She further revealed
that gut microflora of the malnourished child in addition
had a noticeably larger reservoir of antibiotic resistant
genes. In long run, identification of such species can help in
devising appropriate probiotic strategies for eradicating this
menace. Dr. Sesikeran, Director, NIN commented that
microbiota of underweight children could be different
altogether. Dr. Sharmila further stated that microbiota of
Indian children is different from their western counterparts.
Probiotics in maternal and child health
The interplay between both hereditary and environmental
factors play an important role in every stage of develop-
ment from conception to the early postnatal period with
potential long-term effects on mother and child health. The
Grover et al. Gut Pathogens 2012, 4:15 Page 7 of 14
http://www.gutpathogens.com/content/4/1/15gut microbiota as an environmental factor regulates the
development of both metabolic and immune functions
during pre and post neonatal life [20].
This session began with the presentation made by
Dr. Indrani Ganguli, Head, Institute of obstetrics and
Gynaecology, Sir Ganga Ram Hospital, New Delhi who
gave a new touch to the probiotic applications by shifting
the focus from gut health to vaginal health. She show-cased
her interesting findings on the therapeutic role of probiotics
in women’s health particularly in the context of manage-
ment of common vaginal infections. Dr. Ganguli explained
in unequivocal terms that absence or depletion of lactoba-
cilli in vagina could be one of the main reasons for bacterial
vaginosis and the affetcted cases have a significantly
increased risk of HIV, Gonnorrhoea, Chlamydia and Herpes
simplex viral infections. She embarked upon that the use
of probiotic lactobacilli to prevent infection has a good
rationale and an excellent safety record, although, so far
only a few strains have been clinically proven to be effect-
ive. Hence, she emphasized, it is critically important that
strains are characterized and tested clinically using the
delivery system of choice (oral tablets, vaginal pessary,
dried powder or suspension). She pointed out that besides
this, several studies are needed to optimize the defensive
properties of the vaginal microbiota. She finally concluded
her talk with an optimistic note that the health of many
women can be improved by the use of probiotics.
Dr. Ashish Bavdekar, Associate Professor, Department
of Pediatrics KEM Hospital, Pune, in his presentation,
deliberated at length on the outcome of different clinical
meta-analysis studies to demonstrate the efficacy of pro-
biotics against different medical conditions in children.
He began his talk by stating that currently probiotics are
being administered for various indications like general
health improvement, immune enhancement and the
prevention and treatment of specific gut related diseases.
Dr. Bavdekar further elaborated that the evidence for
probiotic efficacy in many such disorders is not so
strong, but there are well established benefits in a small
number of conditions. Based on the data that emerged
from meta-analyses of some clinical studies related to
many diarrheal diseases, he contended that probiotics
specifically Lactobacillus rhamnosus GG, Lactobacillus
reuteri and Saccharomyces boulardii have been shown to
significantly shorten the duration of acute diarrhea espe-
cially acute rotaviral diarrhea by one day and decreased
the number of stools with a beneficial effect starting
after 3 days [21]. Similarly, when used as a preventive
agent, probiotics have shown reduced incidence of Anti-
biotic associated Diarrhea (AAD) by an average of 60%.
The benefits however, were highly strain and dose
dependent. Continuing further debate on the efficacy of
probiotics, Dr. Bavdekar commented that probiotics
have shown a modest benefit in preventing acutegastrointestinal tract infections in healthy infants and
children in child care centers in developed countries. He
also referred to a recent community based clinical trial
conducted in Kolkata, India wherein Lactobacillus casei
Shirota was orally fed to 1–5 years old children [22].
The outcome of the study revealed that daily intake of
this strain showed a protective efficacy of 14% in pre-
venting acute diarrhea. However, as far as prevention of
atopic diseases and IBDs is concerned, there is insuffi-
cient scientific evidence to support probiotic efficacy
against these conditions. Finally after critical appraisal of
the outcome of the meta-analysis studies, he concluded
that overall, the scientific data on all these cases have
largely remained limited and hence, no recommenda-
tions can be made at the moment regarding the use of
probiotics in these conditions.
Dr. Pankaj Garg Consultant, Department of Neonatology,
Centre for Child Health, Sir Ganga Ram Hospital, New
Delhi was the next speaker who delivered a talk on the
application of probiotics in pre terms. The major focus of
his presentation was on the prospects of probiotic therapy
in the management of Necrotizing Enterocolitis (NEC) - a
serious GI disorder occurring in neonates. According to
Dr. Garg, despite significant advancements in the neonatal
care, the mortality resulting from NEC has not improved
over the last three decades as can be reflected from high
mortality rates which continue ranging from 10–30% [23].
Continuing further, he informed the house that there are
only a few interventions which have shown some promise
in the treatment of this life threatening disease. In this
context, breast milk has been recognized as the best option
in the prevention of NEC. However, there is a growing
evidence that supplementation of probiotics to preterm
infants in NICU may provide sufficient relief to the affected
infants [24]. Finding the probiotic therapy an exciting novel
strategy, he commented that the rationale for probiotic
supplementation of preterm infants is based on the data
demonstrating differences in the establishment of intestinal
microbiota in preterm infants. In his opinion, administra-
tion of probiotics to this vulnerable population may be an
effective way to change their gut colonization with the
healthy bacteria and advocated exploring the same for
disease management in preterms. To further support the
efficacy of probiotic supplementation in preterm babies, Dr.
Garg referred to the outcome of a recent meta-analysis
study carried out in India which provided sufficient scien-
tific evidence to establish the efficacy of probiotics in redu-
cing death and disease in preterm neonates [25]. Based on
this study, it was suggested that probiotics should now be
offered as a routine therapy for preterm neonates and that
additional placebo-controlled trials are not warranted.
While concluding his talk, he cautioned that although pro-
biotic supplementation appears to be a promising approach
for prevention of NEC in very low birth weight babies,
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rently, there are no well defined regulatory guidelines in the
country to ensure the safety and quality of commercially
available probiotic preparations. Furthermore, the optimal
probiotic combination and dosing strategy also need to be
clearly elucidated.
Future of probiotics in India - roadmap for research
Dr. Sunita Grover, Principal Scientist at NDRI, Karnal,
India delivered the first talk in this session and shared
her thoughts and vision on reorienting the R&D
program on probiotics and shape the future road map in
the country in carrying forward this mission holistically
through extensive networking and clustering. Since, the
diversity of human gut microbiota from different
geographical regions, ethnicity, different age groups,
populations from different dietary habits and other
niches including the traditional fermented foods has not
been investigated in India at molecular level and no
database is available, it requires extensive efforts from all
the cluster partners from different regions in the country
to work in tandem towards development of Indian
Microbiome database both under healthy and diseased
conditions. Furthermore, in India no indigenous
probiotic strain is available for commercialization and
Indian market is having probiotic products with western
strains. Hence, challenge before Indian researchers is to
develop indigenous probiotic strains whose specific
health claims and safety are scientifically proven and
clinically validated in the target population in India. In
order to achieve this objective, extensive networking and
coordination amongst the researchers working in the
area of probiotics, Microbiology, Molecular Biology, Bio-
technology, Medical Doctors, Nutrition and Dairy and
Food Technology is required to share their expertise to
see this dream come true. Dr. Grover also emphasized
the need for developing an advanced centre of excellence
in probiotic research and product development in the
country to make probiotic research highly competitive
and at par with the advanced countries. According to
her, the centre of excellence should have state of the art
infrastructural facilities to carry out work on genomics,
transcriptomics, proteomics, human gut models etc. The
selection of the strains for functional properties must be
based on strategies using ultra modern molecular tools.
This centre will be wholly responsible for maintenance
of indigenous probiotic strains, build database of gut
microbiota originating from various regions of the
country, proper documentation of probiotic strains with
their functional properties, developing barcoding strategies
for tracking probiotic strains besides providing support to
researchers and industry working in the area of probiotics.
The centre will also look into how to bring indigenous
probiotic strains through developing novel functional foodssupplemented with these strains to rural population
suffering from under nutrition and malnutrition and
other gut related diseases. Besides these, India should
also have effective regulatory framework to put checks
on spurious probiotic products in the country and also
to see that the consumers are not misled.
Dr. Rama Chaudhary Professor, Department of
Microbiology, AllMS, New Delhi, also delivered a talk
in this session and spoke on immune regulation by
gut microbiota. She highlighted the importance of gut
microbiota in different physiological functions in human
gut including immune regulation and mucosal defense.
The interaction between this flora and enterocytes is the
initiating event in immune-modulation. Furthermore, the
gutflora participates in the development of the postnatal
immune system as well as oral tolerance and immunity.
While elucidating the role of commensal gut microbiota
in shaping the gut immunity, Dr. Rama Chadhary elabo-
rated that the gut microbiota acquired during and imme-
diately after birth is necessary for the newborn’s systemic
and mucosal immunity. Quoting from some of the previous
studies, she suggested that shift in the host microbial
community may be associated with number of acute and
chronic diseases including inflammatory bowel diseases,
obesity, cardiovascular diseases, eczema, vaginal infections
etc. She discussed at length how the innate and adaptive
immune response in the gut can be modulated effectively
to manage these chronic inflammatory diseases by manipu-
lating nutritional based strategies including probiotic inter-
ventions. Probiotics can influence the release of specific
cytokines by different cell population as well as the cross-
talk between the epithelium immune cells in the lamina
propria and thus play a fundamental role in mucosal im-
munity. It has also been observed that the specific probiotic
strains can stimulate the secretion of specific cytokines and
facilitate the development of naive T-cells towards a
particular immune pathway and enhance IgA production
and other immunoglobulin in intestinal mucosa. Studies
have demonstrated that host protection against gastro-
enteric infections is provided by these beneficial bacteria
through modulation of pro-inflammatory (e.g. IFNγ and
TNFα) and anti-inflammatory (IL-10) cytokines. Thus,
these characteristics support the preventive and therapeutic
potential of the probiotics or beneficial microbes. She
also shared some of her own data on these lines based on
the outcome of metagenomic studies to demonstrate
immune-modulatory role of probiotics in the management
of common gut related inflammatory diseases.
Novel probiotic foods and formulations-an industrial
perspective
This session was chaired by Dr. V. Prakash, Distinguished
Scientist of CSIR, Mysore. Dr. Karen Scott, from RINH,
University of Aberdeen, Scotland delivered her talk on the
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consequences for health. In her presentation, she brought
to focus dietary substrates playing a key role not only by
influencing the gut microbiota but also the health of the
host. The colonic microbiota degrades dietary substrates
that are undigested or indigestible in the upper GIT, releas-
ing various types of bacterial metabolites, which can either
be beneficial or detrimental for gut health. Continuing
further, she stated that advances in molecular biology tech-
niques have facilitated detailed analyses of the composition
of the bacterial community residing in the lower GIT. Such
analyses have indicated that more than 1000 different
bacterial species colonize an individual and that although,
there is functional consistency in the resident bacterial
groups, there is considerable inter-individual variation at
the species and strain level. To further put forth her view
point, she pointed out that whilst host genome has some
impact on the species composition, dietary factors have a
greater influence, with specific bacterial groups changing in
response to specific dietary interventions. For instance,
the number of the Rosenburia /E. rectale group increases in
the gut following starch supplementation in the diet. Since
the metabolic activities of gut bacterial species differ, and
can also respond to substrate availability, the consequences
for health are dependent on both the specific diet and the
composition of the microbiota. The Roseburia / E. rectale
group are important butyrate producing bacteria, and
butyrate is recognized as one of the most important
bacterial metabolites for health, being both the preferred
energy source for gut epithelial cells and also contributing
to apoptosis of the cancerous cells in the gut [26]. Hence,
any dietary change that can stimulate the growth of these
bacterial species could be beneficial to health. In this
context, she also touched upon the prospects of using pro-
biotics and prebiotic supplementation in the gut which are
considered beneficial for health and are included in an
increasing number of food stuffs. However, before
concluding her talk, she cautioned that there can be inter-
individual differences in the responses to the same
substrate that makes it difficult to generalize the claims
relating to health benefits.
Setting the standards for probiotics: How to meet the
requirements and go beyond?
Probiotics provided as natural ingredients to the food,
dairy, dietary supplement, infant formula and pharma
product have to meet high standards. To maintain high
quality, safety, stability and efficacy of probiotic formu-
lations during the entire processing, production and
storage chain along with post marketing surveillance is
quite challenging and can be achieved only when there
is an effective regulatory framework in operation.
Realizing the importance and need for having appropriate
regulatory standards put in place for probiotics fromconsumer and industry perspective, Dr. Inge Tarnow,
Scientific Advisor, Chr. Hansen A/S Denmark focused her
talk on this topic and gave an overview of the global
scenario of regulatory standards on probiotics. While dis-
cussing the same, she elaborated that probiotics have to be
safe, stable and with proven efficacy before administrating
them to the consumers. According to her, probiotic efficacy
has to be documented in well designed and properly
powered randomized controlled human trials that are
published in peer reviewed scientific journals. Speaking
further on the subject, Dr. Inge advocated that studies
conducted according to International Conference of
harmonization-Good Clinical Practice (ICH-GCP) are the
highest quality standard clinical trials. However, GCP is
not mandatory for credible results. She also mentioned
that due to stricter regulatory environment particularly in
Europe, there is now a demand for high quality clinical
data to obtain approval for health claims on food supple-
ments. Furthermore, it is mandatory for probiotic pro-
ducts to be stable throughout shelf life to ensure efficacy.
Stability data should be provided right from raw material
to the packed consumer product at relevant storage con-
ditions. Safety is of utmost importance and it must be
documented and proven. Finally from an industry per-
spective, probiotic products should preferably be available
in different dosage forms as well as customized solutions.
This can only be accomplished through innovations and
working partnerships. Dr. Inge concluded by suggesting
that the industry has to live up to high quality standards
and requirement set by regulatory bodies to ensure that
consumers receive safe and efficacious products to derive
maximal health benefits and specific health claims.
Dr. Nagendra Shah, Professor of Food Science and
Technology, University of Hong Kong while delivering
his presentation enriched the delegates with an extensive
overview on general and specific health benefits and
safety of probiotic dairy products. Presenting the overall
scenario of the functional food market, he focused on
the various types of bacteria being utilized in the world
for probiotic products formulation. Dr. Shah specifically
mentioned that the most popular probiotic foods such
as probiotic yoghurts contain probiotic bacteria as health
promoting components and stated that the most com-
mon microorganisms used in fermented products belong
to the genera lactococci, leuconostocs, pediococci, lacto-
bacillus’and bifidobacteria. He further briefed the house
that recently probiotics have been incorporated in drinks
and also marketed as supplements including tablets,
capsules and freeze dried preparations. Since a large
number of probiotic bacteria are ingested orally, such a
massive dose can pose a risk to some consumers and
hence may require assurance of safety. Besides this, he
also discussed the risks associated with some of the
probiotic properties used for their selection such as
Grover et al. Gut Pathogens 2012, 4:15 Page 10 of 14
http://www.gutpathogens.com/content/4/1/15adherence to gut epithelial cells, ability to survive in the
gastric conditions and their colonizing potential. He also
highlighted the possibility of probiotic translocation
from gut to the vital organs through blood causing
systemic infections and bacteremia. However, usually
translocation is seen in compromised individuals only.
Other possible risk factor which figured prominently
during the discussions included transfer of antibiotic
resistance associated with probiotics to commensal gut
flora and the potential gut pathogens which can end up
into serious health implications. Hence, safety of probiotic
products must be thoroughly checked to rule out all the
risk factors by testing both in-vitro and in-vivo conditions
using appropriate models and also clinically.Probiotics for adults/elderly
Dr. Colin Hill, Professor of Microbial Food Safety,
Microbiology Department and Alimentary Pharmabiotic
Centre, University College Cork, Ireland in his presentation
shared his recent work on deciphering the possible mech-
anism of action of probiotics in control of infections. He
began his talk by stating that in acute infection, probiotics
may augment the protection afforded by commensal gut
flora through competitive interactions, direct antagonism of
pathogens and or production of antimicrobial factors. He
informed that currently, the major goal of his group is to
identify the precise mode of action of the specific probiotic
effects. In order to analyze the mechanistic basis of the
efficacy of selected probiotics against listeriosis, a highly
infectious and fatal disease, he and his associates used a
mice model system for listeriosis. After mass screening of
probiotic strains, they came out with a promising strain i.e.
Lactobacillus salivarius UCC118 that was very effective in
protecting mice from infection. Interestingly, making
further inroads into their initiative, he disclosed that the
protective effect could be associated with the production of
a bacteriocin by the probiotic strain which kills the Listeria
in the GI tract before it can initiate infection [27] and
claimed that identification of a single molecule for probiotic
effect was the first, and opened the way for many follow up
studies. Further elaborating their work on these lines,
Dr. Hill also spoke about extending their work to examine
the potential of probiotics and antimicrobial compounds in
the treatment of Clostridium difficile - one of the main
causes of Antibiotic Associated diarrhea. The conventional
antibiotic therapy although found effective in mitigating
this disease resulted into a decrease in the proportion of
sequences assigned to the phyla Firmicutes and Bacteriodes
(useful gut flora) with corresponding increase in those
assigned to protobacteria [28] leading to collateral damage.
He also discussed at length one of the possible means to
avoid this collateral damage by application of thiricin CD, a
narrow spectrum bacteriocin produced by Bacillusthuringiensis DPC6431. It was demonstrated that thuricin
CD was equally effective at killing C. difficile in the distal
colon model, but had no significant impact on the compo-
sition of the microbiota. This offers the possibility of
developing a targeted approach to eliminating C. difficile in
the colon without any collateral damage.
Dr. G.P.Talwar, Founder Director, National Institute of
Immunology and the present Director Research, Talwar
Research Foundation, New Delhi delivered his talk on
the role of probiotics in maintaining vaginal and repro-
ductive health. While delivering his presentation, he
touched upon the key role played by lactobacilli to maintain
acidic conditions in vagina at pH 4 to keep it healthy.
Elaborating further, he pointed out that the lactobacilli
occurring in vagina prevent the growth of pathogenic
bacteria by decreasing the pH through production of
D-lactic acid (which unlike L-lactic acid is not metabolized
and hence accumulates in the gut and accounts for acidic
pH), H2O2 and bacteriocins with anti-microbial activity.
However, Dr. Talwar pointed out that, the resident pro-
biotic lactobacilli may disappear under some conditions
such as medication or by any other reason, and the vaginal
pH surges beyond 5 and women become susceptible to
recurring episodes of reproductive tract infections (RTIs).
He also referred to a collaborative study conducted at Sir
Ganga Ram Hospital and All India Institute of Medical
Sciences wherein out of vaginal swabs collected from 210
women suffering from recurring infections whose vaginal
pH was above 5, 126 women were indeed devoid of resi-
dent lactobacilli. However, one or more strains of lactoba-
cilli were isolated from vagina of 84 women. To understand
this anomaly, quantitative studies were carried out on
the D-lactate secreted by strains of lactobacilli isolated
from such women and it was found that the amount of
D-lactate produced by such strains was too low as com-
pared to those isolated from the vagina of healthy
women [29]. Elaborating further on this observation, he
explained the outcome of quantitative studies on the
amount of D-lactic acid made and secreted by the strains
of lactobacilli isolated from infected women. Administra-
tion of probiotic lactobacilli of vaginal origin to RTI
infected women restored the vaginal pH in the acidic
range and protected the subjects from recurrence of
RTIs. Dr. Talwar also discussed the efficacy of three of
the promising strains of lactobacilli in a clinical study
currently in progress at AIIMS and SGRH, New Delhi in
women suffering from recurring episodes of RTIs with
vaginal pH above pH 5. He informed that that the
disease symptoms were cured by intake of a polyherbal
microbicide BASANT followed by administration of 3
billion lactobacilli delivered in a veg. capsule.
Dr. Philip Abraham, Consultant Gastroenterologist, P D
Hinduja National Hospital, Mumbai focused his talk to the
evidence based efficacy of probiotics in gastrointestinal
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to be little more vigilant in establishing the efficacy of
probiotic strains or formulations in terms of specific health
health claims since conflicting conclusions have been
recorded from the outcome of clinical studies largely
attributed to variations in the agents used, their dose and
duration along with evaluation parameter. Dr. Philips
reviewed the findings of some investigators in this regard
based on a recent meta-analysis which compared the effi-
cacy of probiotics across various diseases [21]. Elaborating
further, he particularly referred to some studies wherein
probiotics reduced the risk of acute diarrhea of diverse
causes by one third, more so among children of antibiotic
associated diarrhea by one-half and of travelers’ diarrhea by
8% [30]. However, according to him, their use for preven-
tion of pediatric antibiotic associated diarrhea needs more
evidence. He also spoke about one community study
conducted in India [22] that showed 14% reduction in acute
diarrhea among unprivileged children given L. casei strain
Shirota. Going further into the efficacy of probiotics health
applications from broader perspectives, he stated that
meta-analyses and systematic reviews have shown benefit
in relief of individual symptoms or in global symptoms in
patients with chronic diseases like irritable bowel syndrome
[31], although constipation seems to be the symptom with
least response to probiotic use. He also pointed out that the
VSL#3, a probiotic consortium has been successfully used
for the prevention and treatment of chronic pouchitis [32].
He finally concluded his talk by stating that note must be
made of the fact that many of the observed effects are
strain-specific and conclusions should not be extrapolated
and also emphasized that a benefit-versus-potential risk
must be considered especially in compromised individuals
and in those with serious co-morbidities.
The last speaker in the session Dr. Anders Henriksson,
Senior Application Specialist, Dupoint Nutrition &
Health, Danisco, Australia focused his talk on probiotics
that improve gastrointestinal symptoms. He briefed about
the prospects of exploring the probiotic strains of proven
functional efficacy in the management of Gastrointestinal
(GI) symptoms such as bloating/distension, abdominal
pain and constipation which are commonly associated
with functional bowel disorders (FBD) such as the irrit-
able bowel syndrome (IBS). According to him, FBD’s are
relatively common and it has been estimated that IBS
alone affects 3-25% of otherwise healthy people. Milder
GI symptoms, not classified as FBD, are even more wide
spread. Dr Ander apprised the delegates that Probiotic
strains have been used in several clinical studies [33,34]
on subjects with GI symptoms and further conveyed that
the outcome of such studies suggest that certain probiotic
strains alleviate specific symptoms, particularly bloating/
distension, abdominal pain and constipation. Elaborating
further, he informed that a recent study [35] investigatedthe effect of Bifidobacterium lactis HN019 on the total
GI transit time and a range of GI symptoms. Results
from this study suggest that HN019 reduces the severity
of symptoms by shortening the GI transit time. Results
from another study suggest that certain probiotic strains,
including Lactobacillus acidophilus NCFM, alleviate
symptoms of lactose maldigestion. This effect may be
mediated by microbial enzymes that aid in digestion of
lactose in the upper GI tract. As could be evidenced from
these studies along with others, probiotic cultures may be
used to alleviate not only milder GI symptoms but also
more complex FBD’s. In conclusion, it is anticipated
that a dietary supplementation with this type of probiotic
cultures would bring benefits to those who are affected
by frequent GI symptoms and especially those that are
affected by IBS and other FBD’s.
Panel discussion
This was the last session moderated by Dr. A. K. Srivastava
and the panelists included Drs. Seppo Salminen, Colin Hill,
C.S. Yajnik, V.K.Batish and Sanjeev Ganguly. The key issues
that emerged from the various plenary and technical
sessions formed the subject of panel session and discussed
at length amongst the panelists and the delegates. After
having a thorough brainstorming, some of the crucial issues
in terms of priority formed the basis of the following
recommendations for further follow up action from PAi for
immediate implementation at the governmental level so
that it addresses the interest of all the stake holders.
 Since mother and infant relationship creates the first
truly probiotic microbes transferred from the
mother’s microbiota and breast milk, it is advisable
that mothers should be encouraged to consume
probiotic products that can play an important role
in the development of infants.
 Multicentric well-designed placebo controlled
double blind clinical studies on the target local
population should be conducted at least at two
different locations to establish the functional efficacy
of novel probiotic strains or food formulation
developed with the same for a specific health claim.
 More extensive efficacy and safety studies need to be
carried out on Indian babies before recommending
probiotic interventions for preterm neonates due to
lack of sufficient clinical data available on these lines.
 The origin of the strains can also influence the
efficacy of probiotics against a specific medical
condition for a particular host or community. The
specific probiotic strain originating from the gut of a
particular ethnic community is likely to express its
novel physiological function most optimally in the
native population due to better colonization and
adaptation in the gut relative to a heterologous host
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there is a need to generate adequate comparative
clinical data on efficacy of indigenous strains of
probiotic lactobacilli or bifidobacteria in the local
target population versus the proven probiotic strains
of these organisms originating from western gut to
establish differences in relative efficacy of these
strains of different gut origin with scientific evidence
as proof of this concept.
 Since novel physiological function of probiotics are
highly strain specific, it is very crucial that the
probiotic organisms must be identified accurately at
strain level by using advanced molecular techniques
which can discriminate between the genome of
closely related species and strains of the same
probiotic genera without any ambiguity. In this
context, whole genome sequencing of the probiotic
strain is now recognized as the most authentic gold
standard for probiotic identity.
 The rich microbial diversity of Indian gut needs to
be thoroughly investigated in search of novel
probiotics due to different food habits, geographical,
cultural and anthropological differences and the
ethnicity. For achieving this long term objective, it is
high time that an all India research coordinated
project on these lines should be initiated on priority
by identifying different groups from different
geographical locations in the country through
networking.
 Lactobacillus, Bifidobacterium and Saccharomyces
boulardii, which represent only a fraction of the gut
microbiota, the key members of probiotic group are
the major focus of attention at commercial level
from health perspectives. Therefore, other potential
organisms such as Bacteriodes which constitute the
predominant flora in our gut needs to be targeted in
search of novel probiotics for broader health
applications.
 Selection of potential probiotic strains for product
development is an extremely important pre-requisite
to establish their efficacy and safety in the target
human population. A well designed mass screening
strategy based on specific functional biomarkers and
in vitro tests and in vivo animal models needs to be
worked out to shortlist the most promising strains
for validation in clinical efficacy trials.
 Although, dairy based foods are considered as the
best carriers of probiotics to confer their best health
promoting functions in the consumers, there is a
need to explore other food formulation also for
probiotic supplementation to demonstrate their
health efficacy. Traditional fermented foods which
are already very popular and acceptable amongst the
various ethnic groups in the country could be themost attractive targets that can be explored for
value addition with proven probiotic strains.
 Since viability and stability of probiotic strains is
very crucial to express their health promoting
functions during processing of probiotic food
formulations and in the gut, new innovative
techniques like nano technology and improved food
grade encapsulations need to be investigated for
better performance in the gut functions.
 Although ICMR-DBT guidelines for evaluation of
probiotics in foods have already been put in place in
India, there is an urgent need to evolve effective
Indian regulatory standards based on these
guidelines. In this context, it was felt by all the
concerned participating in the conference that PAi
should establish immediate contact with FSSAI and
expedite the formalities and implementation of
regulatory standards on probiotics in the country in
harmony with the International standards.
Conclusion
This conference – a first of its kind initiative in the country
from Probiotic Association of India was primarily aimed
at fostering probiotic movement in the country by high-
lighting the enormous potentials of probiotics and
probiotic formulations in human health so that the
health benefits attributed to them reach the target
Indian population. In order to realize this dream, the
Conference and the International Symposium on
Probiotics brought together a unique mix of several
national and International experts on probiotics from
leading universities, research institutions, health and
nutritional professionals along with food processing and
pharma Industry. This scientific conglomeration of
almost all the concerned stake holders had made the
conference a perfect platform to share knowledge on
new Innovations and Emerging Trends in this upcoming
area of probiotics. Based on the presentations made by the
eminent speakers and young researchers, it is now well
established that the proven strains of probiotics with the
strongest human health efficacy data duly supported with
adequate scientific evidence can promote human health
in some of the conditions such as rota virus diarrhoea, anti-
biotic associated diarrhoea along with C. difficile diarrhoea,
some other bacterial diarrhoeas and infections besides
lactose intolerance. However, numerous questions have still
remained unanswered and more information is necessary
regarding optimal dosage, duration of therapy origin of
the probiotic strain particularly with regard to their co-
lonization and transit in the gut, strain specificity of health
claims, regulatory issues related to quality, safety and effi-
cacy of individual and combination of probiotics, continued
response rates after withdrawal and the benefits or lack
thereof, of adding probiotics to consumer preparations
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shelf life of the probiotic preparations, including the most
important issue of unravelling their mode of action. These
constitute some of the most pertinent issues that must be
addressed not only for the probiotic supplements as such
but also within the context of the specific disease condi-
tions. Nevertheless, irrespective of these unanswered
questions, probiotics continue to draw lot of attention
amongst the health professionals and consumers find a
new ray of hope in probiotics available in all the formats
in the market to manage their health care and well being.
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